Extended indication Bio101 monotherapy for the treatment of COVID-19 pneumonia in hospitalized adults and the elderly.
Therapeutic value No estimate possible yet
Registration phase No registration expected

Product

Active substance Bio101
Domain Infectious diseases
Reason of inclusion New medicine (specialité)
Main indication COVID-19
Extended indication Bio101 monotherapy for the treatment of COVID-19 pneumonia in hospitalized adults and the elderly.
Manufacturer Biophytis
Mechanism of action Unknown
Route of administration Oral
Therapeutical formulation Capsule
Budgetting framework Extramural (GVS)
Additional remarks Fabrikant: Biophytis

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Particularity Unknown
ATMP No
Submission date 2025
Orphan drug No
Registration phase No registration expected

Therapeutic value

Therapeutic value No estimate possible yet

This assessment does not indicate any potential inclusion in the package.

Dosage per administration BIO101 350mg bid
References NCT04472728

Expected patient volume per year

Patient volume < 10

Market share is generally not included unless otherwise stated.

References Coronadashboard. Rijksoverheid (1); Expertopinie (2).
Additional remarks In 2023 waren er 857 intensive care opnames van COVID patiënten (1). Het aantal patiënten dat mogelijk in aanmerking komt voor dit middel wordt niet hoger ingeschat dan 10 (2).

Expected cost per patient per year

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information